Cargando…

P41 Use of delafloxacin in osteomyelitis: a case report

BACKGROUND: Data and experience with delafloxacin use in osteomyelitis (OM) and other deep-seated infections are limited, yet the burden of OM on healthcare systems is significant. We hereby describe the first case, to our knowledge, of delafloxacin use in OM. CASE DESCRIPTION: A 94-year-old male wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vidwans, Madhuri, Mitria, Andra, Kandil, Hala
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266178/ http://dx.doi.org/10.1093/jacamr/dlad066.045

Ejemplares similares

629. Emergence and Clonal Spread of Delafloxacin-Resistant S. aureus in Brooklyn, NY
por: Malik, Saquib, et al.
Publicado: (2019)

Empirical use of temocillin in hospitalized patients: results from a retrospective audit
por: Kandil, Hala, et al.
Publicado: (2023)

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
por: Hoover, Randall, et al.
Publicado: (2017)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

1588. Delafloxacin Activity Against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin, or Linezolid
por: Saravolatz, Louis D, et al.
Publicado: (2019)

620. Sub-MIC Concentrations of Levofloxacin and Delafloxacin Enhance Staphylococcus aureus Biofilm Formation: Significance of Maximizing Exposure
por: Bodo, Emily C, et al.
Publicado: (2019)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

Updated Review on Clinically-Relevant Properties of Delafloxacin
por: Turban, Adrien, et al.
Publicado: (2023)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
por: Madej, Andrzej, et al.
Publicado: (2019)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)
por: Kaidashev, Igor, et al.
Publicado: (2019)

2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
por: Shortridge, Dee, et al.
Publicado: (2018)

Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program
por: Flamm, Robert K, et al.
Publicado: (2017)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline
por: Kocsis, Béla, et al.
Publicado: (2021)

1463. Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019)
por: Shorttidge, Dee, et al.
Publicado: (2020)

Mental Confusion of Neurological Etiology in 41 cases
por: Brahim, S., et al.
Publicado: (2022)

1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018)
por: Shortridge, Dee, et al.
Publicado: (2019)

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties
por: Jorgensen, Sarah C. J., et al.
Publicado: (2018)

Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values
por: Vialichka, Alesia, et al.
Publicado: (2022)

470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
por: Overcash, J Scott, et al.
Publicado: (2019)

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
por: McCurdy, Sandra P., et al.
Publicado: (2022)

P03-022 - Calprotec in chronic nonbacterial osteomyelitis
por: Brunner, J
Publicado: (2013)

1419. A Rare Case of Clostridium beijerinckii Traumatic Osteomyelitis
por: Doktor, Katherine L, et al.
Publicado: (2019)

Resistance development in Escherichia coli to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin
por: Bösch, Anja, et al.
Publicado: (2023)

In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2017)

2176. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
por: Shortridge, Dee, et al.
Publicado: (2022)

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
por: Kong, Yingying, et al.
Publicado: (2022)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

2377. Outcomes in Patients With History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin And Skin Structure Infection (ABSSSI) With Delafloxacin (DLX) vs. Vancomycin/Aztreonam (VAN/AZ)
por: Oguchi, Godson, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5aua983at4gk7p69s6v40ft6o3